Sutro Biopharma, Inc.
STRO
$1.05
-$0.08-6.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 266.37% | 17.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 266.37% | 17.49% | |||
| Cost of Revenue | 1,577.98% | 101.36% | |||
| Gross Profit | 68.18% | -91.75% | |||
| SG&A Expenses | -22.07% | 46.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.98% | -18.98% | |||
| Operating Income | 131.76% | 27.26% | |||
| Income Before Tax | 84.84% | -8.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 84.86% | -4.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 84.86% | -4.87% | |||
| EBIT | 131.76% | 27.26% | |||
| EBITDA | 137.25% | 28.11% | |||
| EPS Basic | 85.12% | -4.11% | |||
| Normalized Basic EPS | 112.35% | 22.19% | |||
| EPS Diluted | 85.12% | -4.11% | |||
| Normalized Diluted EPS | 112.35% | 22.19% | |||
| Average Basic Shares Outstanding | 1.77% | 0.72% | |||
| Average Diluted Shares Outstanding | 1.77% | 0.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||